Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on February 16, 2010 as doi:10.1124/mol.109.062257

The synthetic cannabinoid WIN sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis by activating p8/CHOP/DR5 axis

O. Pellerito, G. Calvaruso, P. Portanova, A. De Blasio, A. Santulli, R. Vento, G. Tesoriere and M. Giuliano

Dipartimento di Scienze Biochimiche, Università degli Studi di Palermo, Palermo, Italy (O.P., G.C., P.P., A.D.B., A.S., R.V., G.T., M.G.)

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Copyright 2010 by the American Society for Pharmacology and Experimental Therapeutics.

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

Running title: WIN/TRAIL-induced apoptosis in HCC cells

Corresponding author:
Prof. Michela Giuliano
Dipartimento di Scienze Biochimiche, Università di Palermo
Via del Vespro 129
90127 Palermo, Italy
Tel +39 91 6552473, Fax +39 91 6552449
e-mail: mgiulian@unipa.it

Number of text pages: 30 (included references and legends of figures)
number of figures: 7
number of references: 38

number of words in the *Abstract (219)*,
Introduction (647), and
Discussion (1144).

Non-standard abbreviations: HCC, hepatocellular carcinoma; TRAIL, Tumor necrosis factor-related apoptosis inducing ligand; DR4 and DR5, death receptor-4 and -5; CB1 and CB2, cannabinoid receptor 1 and 2; CHOP, CCAAT/enhancer binding protein (C/EBP) homologous protein; COM-1, candidate of metastasis-1; FADD, Fas-associated death domain; IAP, inhibitor of apoptosis protein; PPARγ, peroxisome proliferator activated receptor-gamma; DMSO, dimethyl sulfoxide; MTT, 3-[4,5-dimethylthiazolyl-2] 2,5-diphenyl-tetrazolium bromide assay; $DiOC_6$, 3-3-dihexyloxacarbocyanine; z-VAD, Benzyloxy-carbonyl-Val-Ala-Asp-fluoromethylketone; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

ABSTRACT

In this paper we demonstrate that the synthetic cannabinoid WIN sensitizes human hepatocellular carcinoma (HCC) cells to apoptosis mediated by TNF-related apoptosis inducing ligand (TRAIL). The apoptotic mechanism induced by treatment with WIN/TRAIL combination involved the loss of the mitochondrial transmembrane potential and led to the activation of caspases. In HCC cells WIN treatment induced up-regulation of TRAIL death receptor DR5, an effect which seemed to be related to the increase in the level of p8 and CHOP, two factors implicated in cellular stress response and apoptosis. This relationship was suggested by the observation that the down-regulation of p8 or CHOP by specific siRNAs attenuated both WIN-mediated DR5 up-regulation and the cytotoxicity induced by WIN/TRAIL cotreatment. Moreover, WIN induced a significant decrease in the levels of some survival factors (survivin, c-IAP2 and Bcl-2) and in particular in that of the active phosphorylated form of AKT. This event seemed to be dependent on the transcription factor PPARγ whose level significantly increased after WIN treatment. Therefore, both the induction of DR5 via p8 and CHOP and the down-regulation of survival factors seem to be crucial for the marked synergistic effects induced by the two drugs in HCC cells. Taken together, the results reported in this paper indicate that WIN/TRAIL combination could represent a novel important tool for the therapy of HCC.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

INTRODUCTION

The tumor necrosis factor-related apoptosis inducing ligand (TRAIL), a member of TNF family, is a potent apoptosis-inducing cytokine. TRAIL appears to specifically kill a wide variety of cancer cells in culture and xenografted tumors while sparing most normal cells (Falschlehner et al., 2007; Ray and Almasan, 2003). TRAIL-induced apoptosis is associated with the interaction of this ligand with two closely related membrane receptors, DR4 (TRAIL-R1) and DR5 (TRAIL-R2), while two other TRAIL receptors, DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4), are not involved in apoptotic signal serving as decoy proteins (Sheridan et al., 1997). The binding of TRAIL to DR4 and DR5 receptors results in the interaction with the adaptor molecule FADD leading to the recruitment and cleavage of the initiator caspase-8 and the consequent activation of executioner protease cascade (Kischkel et al., 2000).

It has been demonstrated that many malignant cells are resistant to TRAIL signalling and this is frequently correlated to the loss of TRAIL receptors on cell surface (Zhang and Fang, 2005). Thus, it is important to find therapeutic agents capable of sensitising resistant cancer cells to TRAIL-induced apoptosis. There are many studies demonstrating that the combination of different anticancer agents with TRAIL induces additive or synergistic tumor cell death (Elrod and Sun, 2008; Shamimi-Noori et al., 2008; Griffith and Kemp, 2003; Siegelin et al., 2009). Recently, it has been demonstrated the efficacy of histone deacetylase inhibitors in sensitizing hepatocellular carcinoma (HCC) cells to TRAIL induced apoptosis (Carlisi et al., 2009).

Cannabinoids, originally derived from the plant *Cannabis sativa*, as well as their endogenous and synthetic counterparts, elicit a wide range of central and peripheral effects mostly mediated through cannabinoid receptors CB1 and CB2 which differ in tissue distribution, physiological role and signalling mechanisms (Van der Stelt and Di Marzo 2005; Herkenham et al., 1991). Currently, the interest for cannabinoids is focused on their involvement in the regulation of cell death and survival. The antiproliferative effects of these compounds, observed over 30 years ago,

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

have been reported in various cancer cells, including breast and prostate cancer, PC12 pheochromocytoma, and malignant gliomas (Guzman, 2003; Sarfaraz et al., 2005; Velasco et al., 2004). The action of cannabinoids in tumor cells is related to the decrease in cell viability, proliferation, adhesion and migration, as well as the modulation of angiogenesis and metastasis (Guzman, 2003). Although these results encourage the use of cannabinoids as anticancer agents, the employment is often limited by their psychoactive effects; thus, in the last years, have been developed synthetic CB receptor agonists with activities similar to those exerted by natural cannabinoids but without side effects. Among these, WIN 55,212-2 (R-(+)-(2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrol[1,2,3-de]-1,4-benzoxazin-6-yl)-(1-naphthalenyl) methanone mesylate) (WIN), a synthetic CB1/CB2 receptor agonist, seems to be particularly promising. It has been reported that WIN induces apoptosis in some tumor cell lines, such as human prostate cancer cells and mantle cell lymphoma (Sarfaraz et al., 2006; Gustafsson et al., 2006). Our previous studies demonstrated that WIN is very efficacious in inducing apoptosis in HepG2 cells through a mechanism involving the reduction in the levels of some survival factors (survivin, phospho-AKT, Hsp72 and Bcl-2) and the activation of pro-apoptotic ones (Bax, Bcl-X_S and t-Bid) (Giuliano et al., 2009).

The aim of the present study has been to investigate whether WIN is capable of sensitizing TRAIL-resistant HCC cells to TRAIL-induced apoptosis and to underlie the mechanism by which the combined treatment achieves killing of these cells. Data reported show that the combined treatment with subtoxic doses of WIN and TRAIL dramatically induces apoptosis in three different HCC cell lines. This event seems to be a consequence of two different effects: i) the WIN-induced DR5 up-regulation mediated by p8 and CHOP, two critical mediators of cell death, and ii) the down-regulation of both phospho-AKT and some survival factors of IAP family. Thus, treatment with WIN/TRAIL combination may synergistically stimulate and

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

accelerate death receptor-triggered apoptotic pathway, making this new drug combination promising for clinical outcome.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

MATERIALS AND METHODS

Reagents

R-[2,3-dihydro-5-methyl-3[(4-morpholinyl)methyl] pyrrolo[1,2,3,-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl methanone mesylate (WIN 55,212-2) and GW9662 were purchased from Sigma Chemical Co. Soluble human recombinant TRAIL/APO2L was obtained from Pepro Tech. (EC Ltd, London, UK). Benzyloxy-carbonyl-Val-Ala-Asp-fluoromethylketone (z-VAD-fmk) from Promega (Italy). Stock solutions were prepared in dimethyl sulfoxide (DMSO) and opportunely diluted in culture medium. The final concentration of DMSO never exceeded 0.04%.

Cell cultures

Human HCC HepG2 cells were grown in RPMI 1640 medium, supplemented with 1.0 mM pyruvic acid; Hep3B and SK-Hep1 cells were cultured in Dulbecco's modified Eagle's medium high Glucose (DME/HIGH). 1.0 mM non-essential amino acid solution was added only in Hep3B culture medium. All the media were also supplemented with 2.0 mM L-glutamine, 10% (v/v) heat-inactivated foetal calf serum (FCS) and antibiotic antimycotic solution (100 U/ml penicillin, 100 µg/ml streptomycin and 250 ng/ml amphotericin B, Sigma). Cells were maintained at 37 °C in a humidified atmosphere containing 5% CO_2. For the experiments, cells were seeded at 60-70% confluence, unless otherwise indicated, and allowed to adhere overnight. Then, cells were kept in serum-free medium at least for 6 h before treatments. Control cells were cultured in the presence of vehicle alone.

MTT cell viability assay

The effects on cell viability were determined by 3-[4,5-dimethylthiazolyl-2] 2,5-diphenyl-tetrazolium bromide assay (MTT, Sigma Chemical Co) as previously reported (Giuliano et al., 2009). The absorbance at 570 nm (test wavelength) and at 630 nm (reference wavelength) was

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

measured using an ELISA microplate reader (Dynex Technologies). Cell survival was estimated as a percentage of the control value.

Hoechst staining

The morphological apoptotic changes were analyzed by Hoechst 33258 staining. Cells, seeded in 96-well plates were fixed with methanol/acetic acid (3:1) for 10 min at room temperature, washed in phosphate buffer saline (PBS) and stained for 10 min in PBS containing 40% paraformaldehyde and 10 μg/ml Hoechst 33258. Morphological evaluations of nuclear condensation and fragmentation were performed immediately after staining by means of fluorescent microscope equipped with an automatic photomicrograph system (Leica, Germany).

Flow cytometric analysis of annexin V-FITC/propidium iodide stained cells

Apoptotic cells were quantified by measuring the externalized phosphatidylserine residues by using annexin V-FITC/propidium iodide kit (BD Biosciences, San Diego, CA) following the manufacturer's instructions. After treatment, cells were collected, washed with ice-cold PBS, and suspended in a binding buffer at a concentration of 10^6 cells/ml. Then, cells were incubated for 15 min with FITC-conjugated annexin V and propidium iodide and analyzed by Epics XL flow cytometer (Beckman Coulter) using Expo32 software. Annexin V positive/propidium iodide negative cells (lower right quadrant) were considered to be early apoptotic, while the lower left quadrant contains the vital (double negative) cell population.

Measurement of mitochondrial transmembrane potential ($\Delta\psi_m$)

Mitochondrial transmembrane potential ($\Delta\psi_m$) dissipation was measured by using 3,3-dihexyloxacarbocyanine ($DiOC_6$), a lipophilic fluorochrome which exclusively emits within the spectrum of green light and accumulates in the mitochondrial matrix under the influence of $\Delta\psi_m$.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

After treatment with the drugs, HCC cells were harvested by trypsinization, incubated with 40 nM $DiOC_6$ for 20 min at 37 °C, washed with PBS and analysed by flow cytometry using excitation and emission setting of 488 and 525 nm, respectively. The percentage of cells showing a lower fluorescence, reflecting the loss of $\Delta\psi_m$, was determined by comparison with untreated controls using Expo32 software. Carbonyl cyanide m-chlorophenylhydrazone (CCCP; 50 μM), a protonophore that completely de-energizes mitochondria by dissipating the transmembrane potential, was used as a positive control for maximum $\Delta\psi_m$ disruption (not shown).

Western blotting analysis

After treatment with the compounds, protein extracts were prepared by washing the cells in PBS and incubating for 20 min in ice-cold lysis buffer supplemented with protease inhibitor cocktail, as previously reported (Giuliano et al., 2009). After sonication three times for 10 s and evaluation of protein concentration, equal amounts of protein samples (60 μg/lane) were subjected to SDS-PAGE and then electrotransferred to a nitrocellulose membrane for the detection with specific antibodies. The blots were developed using the alkaline phosphatase colorimetric system. Bands were quantified by densitometric analysis using SMX Image software. The correct protein loading was verified by means of both red Ponceau staining and immunoblotting for β-actin. All the antibodies used were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, Ca, USA), except for anti-caspase-8, -9 and -3 (Cell Signalling, Beverly, Ma, USA), anti-caspase-6 (Sigma, St. Louis, MO) and anti-DR5 (ProSci, Poway, CA).

RT-PCR analysis

Total RNA was isolated from cells using RNeasy Mini kit (Qiagen, Valencia, CA) with a DNase digestion step using the RQ1 RNase free DNase (Promega, Madison, WI). cDNA was subsequently obtained by means of the GeneAmp Kit for reverse transcriptase-polymerase chain

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

reaction (Perkin–Elmer, Foster City, CA) as previously described (Drago-Ferrante et al., 2008). The following sense and antisense primers, respectively, were used to amplify human *p8* gene (5'-GAAGAGAGGCAGGGAAGACA-3' and 5'-CTGCCGTGCGTGTCTATTTA-3'; 571-bp product), human *CHOP* gene (5'-GGCAGCTGAGTCATTGCC-3' and 5'-GCAGATTCACCATTCGGTCA-3'; 496-bp product), and glyceraldehyde-3-phosphate dehydrogenase (*GAPDH)* gene (5'-TGACATCAAGAAGGTGGTGA-3' and 5'-TCCACCACCCTGTTGCTGTA-3'; 200-bp product). PCR reactions were performed using the following parameters: 95°C for 5 minute, 94°C for 30 seconds, 57°C for 30 seconds and 72°C for 1 minute, followed by a final extension step at 72°C for 5 minute. The number of cycles (26-28 cycles for p8, 30 cycles for CHOP and 22-25 cycles for GAPDH) was adjusted to allow detection in the linear range. Samples without reverse transcriptase, RNA or Taq polymerase were employed as internal controls for each RT-PCR assay. PCR products were electrophoresed in 1% agarose gel and visualized by ultraviolet transillumination.

For real-time PCR analysis, cDNA samples were amplified using IQ SYBR Green Supermix (Bio-Rad, Hercules, CA) according to the manufacturer's instructions. The following primers were used: *DR5* gene: sense: 5'-GCACTCACTGGAATGACCTC-3'; antisense: 5'-GCCTTCTTCGCACTGACAC-3' (Ta= 55 °C); *GAPDH* gene: sense: 5'-TGACATCAAGAAGGTGGTGA-3'; antisense: 5'-TCCACCA CCCTGTTGCTGTA-3' (Ta= 55 °C). All reactions were performed in triplicate. For each PCR, we checked linear range of a standard curve of serial dilutions. The relative quantification of DR5 gene expression was evaluated after normalization with GAPDH gene as endogenous control. Data processing and statistical analysis were performed by using IQ5 cycler software.

Small interfering RNAs (siRNAs)

Two different small interfering RNAs against CHOP (siCHOP) (D-004819-01-0005 and D-

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

004819-02-0005) and scrambled siRNA (siScr), as a negative non silencing control, were purchased from Dharmacon (Chicago, IL,USA). P8 siRNA (sip8) (sense 5'-GGAGGACCCAGGACAGGAUd(TT)-3') was obtained from Eurogentec (Serain, Belgium). Cells (2 x 10^5) were plated in six well plates and cultured in antibiotic- and FCS- free RPMI-1640 medium for 24 h before transfection. Then, cells were transfected with 100 nM siCHOP, sip8 or siScr using Metafectene Pro (Biontex, Martinsried/Planegg, GmBH) (6 µl) in a final volume of 1 ml serum-free RPMI. Six hours after transfection, the medium was replaced with fresh RPMI and cells were treated with WIN and TRAIL alone or in combination as indicated. Data reported in Fig. 6 were obtained by using siRNA duplexes D-004819-02-0005 which resulted more efficacious than D-004819-01-0005 in CHOP silencing.

Statistical analysis and evaluation of synergy

Cell viability data were expressed as the mean ± S.E. and evaluated by Student's *t*-test. Differences were considered significant when the *p* values were less than 0.05.

To quantify the effects of drug combination and to determine eventual synergistic actions, the median-effect method, originally described by Chou and Talalay (1984), was employed. Cells were treated with different doses of WIN and TRAIL employed alone or in combination at fixed molar ratios for 24 h. The relative survival was assessed and the concentrations which reduced cell viability of 25%, 50% and 75% (IC_{25}, IC_{50} and IC_{75}) were established. Then, CI values were calculated for different dose-effect levels based on parameters derived from median-effect plots. A CI value significantly < 1 indicates synergy, a CI not significantly different from 1 indicates addition, and a CI significantly >1 indicates antagonism. Synergy is defined as a combination of two agents that has a greater therapeutic effect than would be expected by the simple addition of the individual effects of each drug.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

RESULTS

The synthetic cannabinoid WIN sensitizes HCC cells to TRAIL-induced apoptosis

Our previous results demonstrated that hepatoma HepG2 cells are resistant to TRAIL (Carlisi et al., 2009) while they are sensitive to apoptotic effects induced by the synthetic cannabinoid WIN55,212-2 (WIN) (Giuliano et al., 2009). In the present research we investigated whether WIN could sensitize HCC cells to TRAIL-mediated apoptosis also inducing synergistic effects. For the experiments we employed HepG2, Hep3B and SK-Hep1 cells, three different human HCC lines. Cells were treated for various times with different doses of WIN and TRAIL employed alone or in combination. As reported in Fig. 1A, after treatment with TRAIL (20 or 50 ng/ml) or WIN (2-10 µM) for 24 h, cell viability was only slightly decreased. Instead, WIN/TRAIL combined treatments resulted in a marked reduction in cell viability, which was observed under conditions of a fixed WIN concentration and varied TRAIL concentrations or vice versa. The effect was similar for the three cell lines; however, since HepG2 cells represent a widely employed experimental model of human hepatoma, most of the experiments were performed with this cell line. Time-dependent experiments indicated that the combination of WIN (5 µM) and TRAIL (50 ng/ml) clearly reduced HepG2 cell viability already at 8 h of treatment (-38%) and after 24 h cell viability diminished by about 70% (Fig. 1B). A similar time-course was observed in Hep3B cells while in SK-Hep1 cells the cytotoxic effects appeared more precociously than HepG2 and Hep3B cells (data not shown).

The above reported results suggested that the combination of the two compounds produces synergistic effects. The median effect method of Chou and Talalay (1984) was applied to evaluate the magnitude of the combined effects. At this purpose, increasing doses of WIN and/or TRAIL were employed to determine the amount of the drugs which induces IC_{25}, IC_{50} and IC_{75}, respectively. Then, the combination indices (CI) were calculated for each level of cytotoxicity. In all three examined cell lines great synergistic effects (CI<1) were found already when low

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

doses of WIN and TRAIL were used (Fig. 1C). Since the combination of 5 μM WIN - 20 ng/ml TRAIL significantly reduced HepG2, Hep3B and SK-Hep1 cell viability, this combination was chosen for the subsequent experiments.

The study of cell morphology by means of light microscopy evidenced that WIN/TRAIL combined treatment for 24 h induced the appearance of the typical features of apoptosis in all three HCC cell lines; cells became rounded, detached and floated in the medium (Fig. 1D). Hoechst 33258 fluorescence assay confirmed that the compounds did not induce appreciable modifications when employed alone while when used in combination caused chromatin condensation and fragmentation in the bulk of cells. Similar effects were observed when we evaluated the externalization of phosphatidylserine on the plasma membrane, a typical marker of early apoptosis, by means of annexinV/propidium iodide cytofluorimetric assay. When the two drugs were added together, already at 8 h of treatment, a high percentage of cells (about 40%) were annexin V positive /propidium iodide negative. Fig. 1E and 1F show the results obtained in HepG2 cells, as representative of the effects induced by the drugs in the three cell lines.

Cotreatment of HepG2 cells with WIN and TRAIL causes dissipation of the mitochondrial transmembrane potential and activation of caspases

Next, we analysed whether apoptosis induced by WIN/TRAIL combination was associated with mitochondrial depolarization and activation of caspases. By using $DiOC_6$, a mitochondria-specific and voltage-dependent dye, we evaluated the loss of mitochondrial inner membrane potential ($\Delta\psi m$). The results indicated that treatment of HepG2 cells for 24 h with WIN or TRAIL alone induced only a slight dissipation of $\Delta\psi m$ while when the cells were treated with the combination of the two drugs about 45% of cells resulted depolarized (Fig. 2A).

Western blotting analysis showed that treatment of HepG2 cells for 24 h with WIN/TRAIL combination led to the activation of caspase-8 and caspase-9, resulting in a marked decrease in

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

the respective pro-caspase forms and a concomitant appearance of cleavage products. WIN/TRAIL treatment also induced activation of executioner caspase-6 and caspase-3, as demonstrated by the reduction of the bands related to the inactive forms (Fig. 2B). No significant effect on the levels of the examined caspases was observed when the cells were treated with the two compounds employed separately.

Treatment with WIN/TRAIL combination induces up-regulation of PPARγ and down-regulation of some survival factors

Recently, it has been reported that PPARγ, a member of the nuclear receptor family, which has been shown to possess antineoplastic activity in many cancer cells (Krishnan et al., 2007), can mediate antiproliferative action of cannabinoids (O'Sullivan, 2007), including WIN, as previously demonstrated by us in HepG2 cells (Giuliano et al., 2009). As shown in Fig. 3A, 5 μM WIN significantly enhanced the level of PPARγ in HepG2 cells. The effect, which was already evident at 8 h of treatment, reached the maximum at 24 h. Treatment with 20 ng/ml TRAIL did not modify the level of the transcription factor when employed alone whatever was the incubation time, while when TRAIL was added to WIN, we observed at 8 h of treatment a further increase in PPARγ level. Instead, at 24 h combined treatment induced a decrease in the band corresponding to PPARγ and the appearance of another band at lower molecular weight, presumably a degradation form of the protein. Since z-VAD, the pan inhibitor of caspases, counteracted the appearance of this band, we suppose that PPARγ degradation was a caspase-dependent event occurring in the late phase of apoptosis (Fig. 3A). Also in Hep3B and SK-Hep1 cells WIN induced an increase in PPARγ level, although the effect was less evident and appeared differently in the time.

It is well known that in many cancer cells apoptosis can be inhibited by the expression of high

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

levels of survival factors, including IAP and Bcl-2 family members, and the down-regulation of these proteins is a key event to trigger cell death (LaCasse et al., 2008; Kang and Reynolds, 2009). Thus, we evaluated the effect of WIN and TRAIL, employed alone or in combination, on the level of survivin, c-IAP2, XIAP and Bcl-2. WIN caused a clear reduction in the level of survivin in all three cell lines, while c-IAP2 was clearly reduced in HepG2 and SK-Hep1 cells but not in Hep3B and the level of XIAP and Bcl-2 decreased only in Hep3B and HepG2 cells, respectively. The effects appeared already after 8 h of treatment in concomitance with PPARγ increase, reaching the maximum at 24 h (Fig. 3B). The levels of these survival factors were not modified in the presence of TRAIL alone while the intensity of the corresponding bands further lowered after treatment with WIN/TRAIL combination.

AKT is another important survival factor, vital to the growth and survival of cancer cells. For this reason, drugs which down-regulated AKT pathway can be promising for cancer therapy (Engelman, 2009). Here, we demonstrate that in HepG2 and Hep3B cells the level of the phosphorylated active form of AKT significantly decreased after treatment with WIN for 24 h. The addition of TRAIL potentiated the effect of WIN and in this condition the band corresponding to phospho-AKT almost disappeared. In SK-Hep1 cells the effect was observed only in cotreated cells (Fig. 3B).

Previously, we demonstrated in WIN-treated cells the relationship between the increase in the level of PPARγ and the down-regulation of survival factors by using GW9662, an irreversible antagonist of PPARγ (Giuliano et al., 2009). Here, we observed that the same antagonist, employed at a dose which did not exert any cytotoxicity, also counteracted the effects on survival factors levels in HepG2 and Hep3B cells. Differently, GW9662 was ineffective in SK-Hep1 cells, suggesting that in these cells the down-regulation of these proteins is a PPARγ-independent event (Fig. 3B, lane 5). Interestingly, GW9662 also attenuated by about 30% the cytotoxic effect induced by WIN/TRAIL combination on HepG2 and Hep3B cells, while it did

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

not modify SK-Hep1 cell viability. Fig. 3C reports the effect induced by GW9662 in HepG2 cells.

WIN induces DR5 up-regulation sensitizing HCC cells to TRAIL action

It is well known that TRAIL resistance is often associated with the loss of the specific DR4 and DR5 death receptors or the up-regulation of the decoy DcR1 and DcR2 receptors (Sheridan et al., 1997). Since the expression of these proteins can be modulated by a number of compounds, we were interested in determining their levels in 5 μM WIN-treated HCC cells. Fig.4A shows that at 24 h of treatment, WIN induced an increase in the levels of DR4 and, in particular, in that of DR5, while the levels of DcR1 and DcR2 were only slightly decreased following treatment (not shown).

Our experiments demonstrated that in HepG2 cells, as well as in Hep3B and SK-Hep1 cells, WIN-induced DR5 increase was progressive with time; the effect was clearly evident at 8 h of treatment reaching the maximum at 16 and 24 h (Fig. 4B). DR5 increase was a consequence of the transcriptional activation induced by WIN treatment. In fact, real-time quantitative RT-PCR for DR5 mRNA expression, performed in HCC cells, showed that 5 μM WIN increased the level of DR5 transcript reaching about two fold the control value already at 8 h of treatment (Fig. 4C). The effects on both DR5 mRNA and protein levels were specifically induced by the cannabinoid, in fact, the addition of TRAIL did not modify WIN effects (Fig. 4C and 4D, upper panel).

It has been documented that in cancer cells, the down-regulation of c-FLIP, an antiapoptotic factor related to death receptors, can contribute to enhancement of TRAIL-induced apoptosis (Park et al., 2009). Western blotting analysis showed that WIN induced a marked down-regulation of both the long and short isoforms of the protein. Also in this case the effect obtained in WIN-treated cells was not modified by TRAIL (Fig. 4D, lower panel). The addition of GW9662 partially counteracted WIN effect on c-FLIP level, indicating that this event is almost

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

in part dependent on PPARγ activation.

WIN-induced DR5 up-regulation is a CHOP-dependent event.

Next, we were interested to investigate the underlying mechanism by which WIN induces DR5 up-regulation. It has been demonstrated that in hepatic stellate cells DR5 up-regulation is regulated by PPARγ (Wang et al., 2009). The addition of PPARγ inhibitor GW9662 to WIN/TRAIL-treated cells failed to counteract WIN-induced increase in both mRNA and protein DR5 levels (Fig. 4C and 4D), indicating that, in our experimental model, DR5 increase is a PPARγ-independent event.

Another upstream activator of DR5 in certain types of cancer is CHOP (also known as GADD153), a transcription factor of C/EBP homologous protein family, which is strictly correlated with endoplasmic reticulum (ER) stress and participates to ER-mediated apoptosis (Chen et al., 2007). Results reported in Fig. 5A show that in HCC cells CHOP level was significantly increased after WIN treatment in a time-dependent manner. The event was clearly evident at 8 h in accordance with the cannabinoid-induced DR5 increase. CHOP up-regulation occurred at the transcription level, as demonstrated by semi-quantitative RT-PCR analysis (Fig. 5B). The effects on CHOP expression were induced by the cannabinoid alone; in fact, also in this case, the addition of TRAIL did not modify WIN effects on CHOP mRNA and protein levels (Fig. 5B and 5C). Since it has been described that up-regulation of CHOP and DR5 can be dependent on ROS generation (Lee et al., 2009), we examined the effects induced by the addition of N-acetylcysteine or GSH on both the viability of WIN/TRAIL-treated cells and the levels of DR5 and CHOP. The results seemed to exclude the involvement of oxidative stress; in fact the examined parameters were unmodified after the addition of the anti-oxidants (not shown).

It has been recently identified a correlation between CHOP and p8 (also designated as COM-1 or

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

nuclear protein-1), a stress-regulated protein, which is implicated in a number of functions including the induction of apoptosis in tumor cells (Chowdhury et al., 2009; Carracedo et al., 2006). As p8 is an essential mediator of cannabinoid antitumor action in gliomas (Carracedo et al., 2006), we tested the involvement of this factor in the antiproliferative effect of WIN in HCC cells. Semi-quantitative RT-PCR demonstrated that p8 mRNA levels increased after 8 h of WIN treatment in all three cell lines. P8 up-regulation seemed to be more evident in Hep3B and SK-Hep1 cells because in these cells the basal level of p8 mRNA was almost undetectable. The increase was also observed in WIN/TRAIL-treated cells while it was not observed in the presence of TRAIL alone (Fig. 5B).

To clarify whether p8 and CHOP proteins are critical for WIN-mediated DR5 up-regulation, we down-regulated the expression of these factors by small interfering RNA targeted against CHOP (siCHOP) or p8 (sip8) mRNAs and examined the effect on DR5 activation and cell death in response to WIN and TRAIL, employed alone or in combination. In initial experiments, CHOP expression was evaluated in siCHOP transfected WIN-treated HepG2 cells. Fig. 6A shows that the transfection with siCHOP reduced WIN-dependent CHOP up-regulation as compared to treated cells transfected with a scrambled negative control siRNA (siScr). Similarly, siCHOP also clearly abrogated WIN-induced DR5 increase both at mRNA and protein levels, confirming that CHOP up-regulation is required for this event (Fig. 6A and 6B).

To evaluate the existence of a p8/CHOP/DR5 axis, we also studied the effect of WIN after silencing of p8 expression. After to have confirmed the reduction in the level of p8 transcript in the presence of the specific siRNA (Fig. 6C), we studied in sip8 transfected cells the levels of CHOP and DR5 after WIN treatment. As shown in Fig. 6D, the levels of both these factors were significantly decreased in WIN-treated transfected cells.

Importantly, we found that in siCHOP or sip8 transfected HepG2 cells, WIN/TRAIL combined treatment exerted a minor cytotoxic effect than that observed in cells transfected with scrambled

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

siRNA (Fig. 6E).

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

DISCUSSION

The aim of this study was to investigate the effect of cannabinoids in modulating TRAIL sensitivity and in activating apoptosis in TRAIL-resistant HCC cells. Data presented in this paper demonstrate for the first time a strong synergistic interaction between WIN, a synthetic ligand of cannabinoid receptors, and TRAIL in HCC cell lines. Treatment with combination of subtoxic doses of the two drugs effectively reduced the viability of HepG2, Hep3B and SK-Hep1 cells, three HCC cell lines characterized by a different origin and tumorigenic degree. Cell death observed after treatment with WIN/TRAIL combination was associated with the activation of an apoptotic pathway which involved the dissipation of transmembrane mitochondrial potential and the activation of caspase activities.

Our paper clearly indicates that many events induced by WIN can be responsible for sensitization of HCC cells to TRAIL-induced apoptosis. The results provided evidence that treatment with WIN potently and rapidly up-regulated TRAIL receptor DR5, at both mRNA and protein expression levels, an event which is involved in the sensitization to TRAIL-induced apoptosis by different compounds. DR5 up-regulation was accompanied by activation of caspase-8 and decrease in c-FLIP level, an antiapoptotic protein that operates as an endogenous antagonist of caspase-8.

In order to ascertain the molecular mechanism through which WIN enhanced DR5 expression, at first, we hypothesized an involvement of PPARγ. This hypothesis was suggested by the observation that PPARγ, a factor which is precociously increased by WIN treatment, has been shown to enhance DR5 expression in hepatic stellate cells (Wang et al., 2009). However, in line with other authors (Zou et al., 2007; Kim et al., 2008a) data obtained by using the specific PPARγ inhibitor GW9662 demonstrated that in HCC cells the increase in DR5 level was a PPARγ-independent event.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

CHOP is a key transcription factor involved in apoptosis induced by many events, such as reticulum stress, DNA-damage, nutrient starvation or anticancer drugs (Oyadomari and Mori, 2004). Recently, it has been demonstrated a relationship between the up-regulation of CHOP and the increase of DR5. Such an event seemed to be responsible for re-activation of TRAIL signaling in tumor cells (Yoshida et al., 2005). Moreover, Carracedo et al. (2006) showed that in glioma cells, as well as in many other tumor cell lines, CHOP up-regulation can be also mediated by tetra-hydrocannabinol. In line with these observations, our data indicate that WIN treatment markedly augmented mRNA and protein levels of CHOP already after 8 h of treatment in concomitance with the increase in the level of DR5. This effect was also observed in WIN/TRAIL cotreated cells. The role of CHOP/DR5 axis in apoptosis induced by combined treatment was also suggested by the observation that knockdown of CHOP induced by siRNA significantly down-regulated DR5 level and concomitantly reduced cell death induced by WIN/TRAIL. Therefore, we conclude that CHOP is a key player in this mechanism.

CHOP up-regulation was often related to ROS increase as demonstrated in human renal cancer cells treated with withaferin A (Lee et al., 2009). However, in other cases, as shown in glioma cells treated with arsenic trioxide (Kim et al., 2008b), CHOP up-regulation was a ROS-independent event. In accordance with these authors, our results seemed to exclude the involvement of oxidative stress as CHOP inducer in HCC cells treated with WIN, because the addition of N-acetylcysteine and reduced glutathione, which are two powerful antioxidants, did not modify the effects of WIN on apoptosis as well as on the levels of both CHOP and DR5.

In order to individuate the mechanism responsible for the enhancement in the expression of CHOP, we evaluated the possible involvement of p8, an endoplasmic reticulum-stress regulated protein, which it has been recently demonstrated to mediate cannabinoid action in tumor cells (Carracedo et al., 2006). Experimental evidence reported in the present study make plausible the hypothesis that p8 increase can be responsible for CHOP up-regulation. In fact, p8 transcript was

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

markedly increased after treatment of HCC cells for 8 h with WIN and after p8 silencing the WIN-dependent up-regulation of both CHOP and DR5 was significantly reduced. However at now, we do not know the mechanism by which WIN triggers p8 activity; it is possible to suppose the involvement of ceramide also in these cells, as demonstrated in glioma cells treated with tetra-hydrocannabinol (Carracedo et al., 2006). Studies are in progress to evaluate the level of de novo synthesized ceramide in HCC cells treated with WIN.

Another mechanism by which WIN can sensitize HCC cells to WIN/TRAIL-mediated apoptosis seems to be related to the decrease in the level of survival factors. In many experimental models, the down-regulation of these proteins represents a way to address apoptosis by anticancer drugs. Here, we demonstrate that in HCC cells, WIN induced a clear reduction in the level of phosphorylated active form of AKT, which can be considered as a crucial factor for the growth and survival of human cancer cells. Also some members of IAP family and Bcl-2 were down-regulated following WIN treatment. These events seemed to be mediated by PPARγ, whose levels were early up-regulated by WIN treatment. In HepG2 and Hep3B cells the employment of the specific PPARγ antagonist (GW9662) counteracted the decrease in survival factors and in concomitance partially counteracted WIN/TRAIL effect on cell viability, indicating that the down-regulation of survival factors is in these cells a PPARγ-dependent event. The addition of TRAIL slightly potentiated the effects of WIN on PPARγ and survival factor levels at 8 h of treatment. This event could be related to β-catenin whose levels are very high in hepatoma cells. In fact, it has been recently demonstrated that this factor is a negative regulator of PPARγ gene expression (Almeida et al., 2009) and that, in resistant cancer cells, TRAIL- and troglitazone-induced apoptosis is preceded by a caspase-dependent cleavage of β-catenin (Senthivinayagam et al., 2009). Thus, it is plausible to hypothesize that also in hepatoma cells the further increase in PPAR-γ level could be dependent by the cleavage of this protein induced by WIN/TRAIL

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

combined treatment.

Although treatment with WIN/TRAIL combination resulted efficacious in all three hepatoma cell lines, the comparative study evidenced some differences. In particular, in SK-Hep1 cells the expression of the survival factors was differently influenced by treatment and seemed to be independent of WIN-induced PPARγ up-regulation. We have undertaken a research to investigate the causes of the observed differences.

In conclusion, data reported in this paper indicate that in apoptosis induced by WIN/TRAIL combination two different mechanisms are involved: on the one hand, the WIN-mediated early activation of p8 and CHOP causes up-regulation of TRAIL receptor DR5 thus sensitizing resistant HCC cells to TRAIL; on the other hand, WIN treatment through enhancement of PPARγ leads to down-regulation of survival factors further contributing to cell death (Fig. 7). Although other studies will be required to support an eventual clinical application of WIN/TRAIL cotreatment, this novel drug combination may represent, in our opinion, a promising anticancer strategy.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

REFERENCES

Almeida M, Ambrogini E, Han L, Manolagas SC, and Jilka RL (2009) Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-gamma expression, and diminished pro-osteogenic Wnt signaling in the skeleton. *J Biol Chem.* **284**: 27438-48.

Carlisi D, Lauricella M, D'Anneo A, Emanuele S, Angileri L, Di Fazio P, Santulli A, Vento R, and Tesoriere G (2009) The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. *Eur. J. Cancer* **45**: 2425-2438.

Carracedo A, Lorente M, Egia A, Blázquez C, García S, Giroux V, Malicet C, Villuendas R, Gironella M, González-Feria L, Piris MA, Iovanna JL, Guzmán M, and Velasco G (2006) The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. *Cancer Cell* **9**: 301-312.

Chen S, Liu X, Yue P, Schönthal AH, Khuri FR, Sun SY (2007) CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells. *Mol Pharmacol* **72**: 1269-1279.

Chou TC, and Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. *Adv Enzyme Regul* **22**:27-55.

Chowdhury UR, Samant RS, Fodstad O, and Shevde LA (2009) Emerging role of nuclear protein 1 (NUPR1) in cancer biology. *Cancer Metastasis Rev* **28**: 225-232.

Drago-Ferrante R, Santulli A, Di Fiore R, Giuliano M, Calvaruso G, Tesoriere G, and Vento R. (2008) Low doses of paclitaxel potently induce apoptosis in human retinoblastoma Y79 cells by up-regulating E2F1. *Int J Oncol* **33**: 677-687.

Elrod HA, and Sun SY (2008) Modulation of death receptors by cancer therapeutic agents. *Cancer Biol Ther*. **7**: 163-173.

Engelman JA. (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. *Nat Rev Cancer* **9**: 550-562.

Falschlehner C, Emmerich CH, Gerlach B, and Walczak H (2007) TRAIL signalling: decisions between life and death. *Int J Biochem Cell Biol* **39**: 1462-75.

Giuliano M, Pellerito O, Portanova P, Calvaruso G, Santulli A, De Blasio A, Vento R, and Tesoriere G (2009) Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: involvement of the transcription factor PPARgamma. *Biochimie* **91**: 457-465.

Griffith TS, and Kemp TJ (2003) The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis. *Cancer Chemother Pharmacol*. **52**: 175-184.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

Gustafsson K, Christensson B, Sander B, and Flygare J (2006) Cannabinoid receptor-mediated apoptosis induced by R(þ)-methanandamide and Win55,212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma. *Mol. Pharmacol* **70**: 1612-1620.

Guzman M (2003) Cannabinoids: potential anticancer agents. *Nat Rev Cancer* **3**: 745-755.

Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, and Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. *J Neurosci* **11**: 563-583.

Ray S, Almasan A (2003) Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. *Cancer Res* **63**: 4713-4723.

Kang MH, and Reynolds CP (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. *Clin Cancer Res* **15**: 1126-1132.

Kim YH, Jung EM, Lee TJ, Kim SH, Choi YH, Park JW, Park JW, Choi KS, and Kwon TK (2008a) Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. *Free Radic Biol Med* **44**: 1055-1068.

Kim EH, Yoon MJ, Kim SU, Kwon TK, Sohn S, and Choi KS (2008b) Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation. *Cancer Res* **68**: 266-275.

Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, and Ashkenazi A (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. *Immunity*. **12**: 611-620.

Krishnan A, Nair SA, and Pillai MR (2007) Biology of PPAR gamma in cancer: a critical review on existing lacunae. *Curr Mol Med* **7**: 532-540.

LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, and Korneluk RG (2008) IAP-targeted therapies for cancer. *Oncogene* **27**: 6252-6275.

Lee TJ, Um HJ, Min do S, Park JW, Choi KS, and Kwon TK (2009) Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. *Free Radic Biol Med* **46**: 1639-1649.

O'Sullivan SE (2007) Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. *Br J Pharmacol* **152**: 576-582.

Oyadomari S, and Mori M (2004) Roles of CHOP/GADD153 in endoplasmic reticulum stress. *Cell Death Differ* **11**: 381-389.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, and Kim SH (2009) Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway. *Biochem Pharmacol* **77**: 1328-1336.

Sarfaraz S, Afaq F, Adhami VM, and Mukhtar H (2005) Cannabinoid receptor as a novel target for the treatment of prostate cancer. *Cancer Res* **65**: 1635-1641.

Sarfaraz S, Afaq F, Adhami VM, Malik A, and Mukhtar H (2006) Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. *J Biol Chem* **281**: 39480-39491.

Senthivinayagam S, Mishra P, Paramasivam SK, Yallapragada S, Chatterjee M, Wong L, Rana A, and Rana B (2009) Caspase-mediated cleavage of beta-catenin precedes drug-induced apoptosis in resistant cancer cells. *J Biol Chem.* **284**:13577-88.

Shamimi-Noori S, Yeow WS, Ziauddin MF, Xin H, Tran TL, Xie J, Loehfelm A, Patel P, Yang J, Schrump DS, Fang BL, and Nguyen DM (2008) Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway. *Cancer Gene Ther*. **15**: 356-370.

Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, and Ashkenazi A (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. *Science*. **277**: 818-821.

Siegelin MD, Reuss DE, Habel A, Rami A, and von Deimling A (2009) Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. *Neuro Oncol*. **11**: 122-131.

Van der Stelt M, and Di Marzo V (2005) Cannabinoid receptors and their role in neuroprotection. *Neuromol Med* **7:** 37-50.

Velasco G, Galve-Roperh I, Sanchez C, Blazquez C, and Guzman M (2004) Hypothesis: cannabinoid therapy for the treatment of gliomas? *Neuropharmacol* **47:** 315-323.

Wang X, Huang G, Mei S, Qian J, Ji J, and Zhang J (2009) Over-expression of C/EBP-alpha induces apoptosis in cultured rat hepatic stellate cells depending on p53 and peroxisome proliferator-activated receptor-gamma. *Biochem Biophys Res Commun* **380**: 286-291.

Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, and Sakai T (2005) Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. *Cancer Res* **65**: 5662-5667.

Zhang L, and Fang B (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. *Cancer Gene Ther* **12**: 228-237.

Zou W, Liu X, Yue P, Khuri FR, and Sun SY (2007) PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. *Cancer Biol Ther* **6**: 99-106.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

FOOTNOTES

G.T. and M.G. share senior co-authorship.

This work was supported by University of Palermo [Grant ORPA07EZ5Z and ORPA06F3TB]. Dr. Ornella Pellerito is supported by a fellowship by AIRC (Associazione Italiana per la Ricerca sul Cancro). The authors thank Dr. Antonella D'Anneo for comments on the manuscript.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

LEGENDS OF FIGURES

Figure 1. WIN sensitizes HCC cells to TRAIL-induced apoptotic cell death. (A) Effect of WIN and/or TRAIL on HepG2, Hep3B and SK-Hep1 cell viability. Cells were treated with WIN and/or TRAIL for 24 h at the indicated concentrations. **(B)** Time-dependent effect of WIN and/or TRAIL on HepG2 cell viability. Cell viability was estimated by MTT assay as reported in Methods and expressed as the percentage of control value. Data are the means ± S.E. of four independent experiments involving triplicate assays. ***p*< 0.01 versus control untreated cells. **(C)** Synergistic effects exerted on HepG2 cells by WIN/TRAIL combinations. HepG2 cells were treated for 24 h with the two compounds at concentrations which changed in a fixed ratio. At the end of treatment, cytotoxic effects were measured and data were employed to calculate combination index (CI) at the different fractional effects as reported in Methods.
(D) Morphological changes of HepG2, Hep3B and SK- Hep1 cells observed under light microscopy. **(E)** Hoechst 33258 fluorescence assay to detect typical DNA condensation in HepG2 cells. Cells were treated for 24 h with the drugs employed at the indicated concentrations. **(F)** Flow cytometric analysis of annexin V/propidium iodide labelled HepG2 cells treated for 8 h, as indicated. Then, annexin V-FITC and propidium iodide were added as described in the manufacturer's instructions. A flow cytometric analysis was performed to quantify the percentage of live and early apoptotic cells. In D, E and F, representative data from at least three different experiments with similar results are shown.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Figure 2. WIN/TRAIL combined treatment induces mitochondrial transmembrane potential dissipation and activation of caspases. (A) Evaluation of mitochondrial transmembrane potential (ΔΨm) dissipation in HepG2 cells treated for 24 h with 5 µM WIN and 20 ng/ml TRAIL employed alone or in combination. ΔΨm was quantified by flow cytometry as reported in Methods. **(B)** Activation of caspase activities in HepG2 cells treated with WIN and/or

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

TRAIL for 24 h. Cell lysates were analysed by Western blotting using specific antibodies against the different caspase activities as reported in Methods. Actin blots were included to show equal protein loading for all the samples. The results are representative of four independent experiments with similar results.

Figure 3. WIN-sensitized TRAIL-mediated apoptosis is accompanied by up-regulation of PPARγ and down-regulation of survival factors. **(A)** Effects induced by WIN or TRAIL, employed alone or in combination, on PPARγ level in HCC cells treated for 8 and 24 h in the presence of absence of z-VAD. **(B)** Effects induced by the compounds on the level of the survival factors survivin, c-IAP2, XIAP, Bcl-2, phospho-AKT. HCC cells were treated for 24 h with the two compounds employed alone or in combination in the presence or absence of the PPARγ inhibitor GW9662 as indicated. Cell lysates were prepared as reported in Methods, resolved by SDS-PAGE and Western blotting. Actin blots were included to show equal protein loading for all the samples. The results are representative of four independent experiments with similar results. **(C)** Effect induced by 50 μM GW9662 on viability of HepG2 cells treated for 24 h with WIN/TRAIL combination. Cell viability was estimated by MTT assay, as reported in Methods, and expressed as the percentage of control cells. Data were the means ± S.E. of four independent experiments involving triplicate assays. ** $p < 0.01$ versus control untreated cells.

Figure 4. WIN induces up-regulation of both mRNA and protein expression levels of DR5 death receptor. **(A)** Evaluation of DR5 and DR4 TRAIL receptors in HCC cells treated with WIN for 24 h. **(B)** Time-dependent effect on the level of DR5 induced by WIN treatment in HepG2 cells. **(C)** Real-time RT-PCR to evaluate the effect of the compounds on the level of DR5 transcript in HCC cells treated for 8 h in the presence or absence of 50 μM GW9662. Real-time RT-PCR was performed as reported in Methods. **(D)** Effects of WIN/TRAIL combined treatment

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

on the level of DR5 and c-FLIP measured in HepG2 cells incubated for 24 h with the compounds in the presence or absence of 50 μM GW9662.

Western blotting analysis was performed as reported in Methods. Actin blots were included to show equal protein loading for all the samples. The results are representative of four independent experiments with similar results.

Figure 5. The apoptotic effects of WIN/TRAIL combination are dependent on up-regulation of CHOP and p8. (**A**) Time-dependent increase in the level of CHOP induced by 5 μM WIN in HCC cells. (**B**) CHOP and p8 are transcriptionally induced by WIN treatment. HCC cells were treated for 8 h with WIN and/or TRAIL at the indicated concentrations. The expression of CHOP and p8 transcripts was determined by semiquantitative RT-PCR. GAPDH mRNA levels were evaluated as an internal control. Results are representative of at least three separate experiments. **(C)** Effects induced by WIN and/or TRAIL in HepG2 cells after 24 h of treatment. CHOP expression level was analyzed by western blotting analysis as reported in Methods. Actin blots were included to show equal protein loading for all the samples.

Figure 6. RNA interfering against CHOP or p8 affected DR5 expression and HepG2 cell viability. (**A**) Western blotting analysis of CHOP and DR5 expression levels and (**B**) real-time RT-PCR for DR5 mRNA in siCHOP transfected cells. (**C**) Semi-quantitative RT-PCR of p8 transcripts and (**D**) western blotting analysis of the levels of CHOP and DR5 in sip8 transfected cells. HepG2 cells were transfected for six hours with CHOP siRNA (siCHOP), p8 siRNA (sip8) or scrambled control siRNA (siScr). At the end, cells were treated with 5 μM WIN for other 8 h for evaluation of p8 mRNA or 16 h for CHOP and DR5 protein expression levels. The results are representative of three independent experiments with similar results. **(E)** Knockdown of CHOP or p8 expression attenuated cytotoxic effect of WIN/TRAIL combined treatment. siCHOP or

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

sip8 transfected HepG2 cells were treated with 5 μM WIN /20 ng/ml TRAIL for 24 h. Cell viability was estimated by MTT assay as reported in Methods and expressed as the percentage of control value. Data were the means ± S.E. of three independent experiments involving triplicate assays.

Figure 7. Schematic representation of the proposed mechanism of WIN/TRAIL -induced apoptosis on HCC cells.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 1



Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Figure 2

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.



Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 3



Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Figure 4

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.



Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 5



Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Figure 6

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.



Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024

Molecular Pharmacology Fast Forward. Published on February 16, 2010 as DOI: 10.1124/mol.109.062257
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 7



Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 18, 2024